

**Short Communication**

**Cloning and molecular characterization of *Omp31* gene from *Brucella melitensis* Rev 1 strain**

**Yousefi, S., Sekhavati \*, M.H., Tahmoorespur, M., Abbassi-Dalooi, T.**

*Department of Animal Sciences, Faculty of Agriculture, Ferdowsi University of Mashhad, Mashhad, Iran*

Received 16 January 2014; accepted 14 September 2014  
Corresponding Author: hadisekhavati@gmail.com

---

**ABSTRACT**

Brucellosis, caused by the genus *Brucella* bacterium, is a well-known infection among domestic animals. Considering the serious economic and medical consequences of this infection, various preventive efforts have been made through using recombinant vaccines, based on outer membrane protein (OMP) antigens of *Brucella* species. The objective of the present study was to clone, analyze the sequence, and predict the epitopes of *Omp31* gene as a major *B. melitensis* antigen. The full-length open reading frame (ORF) for this gene was amplified by specific primers and cloned into the pTZ57R/T vector. The gene sequence of *B. melitensis* Rev 1 strain was submitted to NCBI database. The results of phylogenetic analysis showed that *Omp31* is almost similar in different *Brucella* species. Online prediction software programs were also used to predict B- and T-cell epitopes, secondary and tertiary structures, antigenicity, and enzymatic degradation sites. The bioinformatic tools in the current study were confirmed by the results of three different experimental epitope prediction studies. Bioinformatic analysis identified one T-cell and three B-cell epitopes for *Omp31* antigen. Finally, based on the antigenicity and proteasome recognition sites, common B- and T-cell epitopes were predicted for *Omp31* (amino acids 191-204). Bioinformatic analysis showed that these regions had proper epitope characterization and could be useful for recombinant vaccine development.

**Keywords:** *Brucella melitensis*, *Omp31*, Bioinformatic analysis

---

**INTRODUCTION**

Brucellosis, which is regarded as a common zoonotic disease and a public health issue, has economic consequences for many developing countries (Karthik et al., 2013). This infection caused by *Brucella* bacterium, a genus of Gram-negative bacteria, can primarily affect domestic animals (Cutler et al., 2005).

In animals, brucellosis is characterized by abortion and reduced fertility, while in humans, it manifests with chronic infections and symptoms such as undulant fever, arthritis, and osteomyelitis (Pappas et al., 2006). The outer membrane proteins (OMPs) of *Brucella* bacterium are cell-specific surface antigens, which have extremely remarkable immunogenic characteristics. MPs are excellent candidates for the development of

brucellosis recombinant vaccines. These cell surface antigens are classified into two major groups: 1) OMP2a and OMP2b, and 2) OMP25 and OMP31 (Gupta et al., 2012). The open reading frame (ORF) of *OMP31* gene was initially cloned from *B. melitensis* 16M strain, and its predicted amino acid sequence exhibited significant homology to *OMP25* gene (34% sequence identity) (Vizcaino et al., 1996). In addition, according to previous research, *Omp31* could be used as an experimental gene in protection assays to determine its potential as a vaccine candidate (Vahedi et al., 2011; Azimi et al., 2012; Ghasemi et al., 2013). The immune system in the human body produces antibodies which specifically attach to identified regions of antigens, known as epitopes (Berzofsky, 1985). In general, epitopes may be classified as B-cell (continuous and discontinuous) and T-cell (MHC-I and MHC-II) epitopes (Zhang et al., 2012). Continuous or linear epitopes are composed of consecutive amino acids, whereas discontinuous epitopes constitute spatially folded amino acids which lie far away in the primary sequence (Ponomarenko and van Regenmortel, 2009). T-cell epitopes are antigenic peptide strings, recognized by T-cell receptors (Chen et al., 2011). B- and T-cell epitopes, which could be predicted via computational tools, are widely applied in antibody production, immunodiagnosics, development of epitope-based vaccines, selective deimmunization of therapeutic proteins, and autoimmunity (Steere et al., 2011). These cost-effective, advantageous, and feasible tools could also replace experimental methods which are costly and time-consuming (Ponomarenko and van Regenmortel, 2009). Today, several epitope prediction software programs are available. The first generation of these prediction tools was supported by motif-based algorithms (Chen et al., 2011), primary amino acid sequence of antigens (Hopp and Woods, 1981), or other physiochemical protein characteristics. Recently, more sophisticated methods have been developed, using various machine learning algorithms, based on support vector machines (Donnes and Elofsson, 2002), hidden

Markov model (Noguchi et al., 2002), and artificial neural networks (Buus et al., 2003). The objective of the present study was to clone, analyze the sequence, and predict the epitopes of *Omp31* as a *B. melitensis* antigen. Finally, B- and T-cell epitopes were used for designing an epitope-based vaccine.

## MATERIALS AND METHODS

### **Bacterial strains, growth conditions, and isolation.**

In the current study, *B. melitensis* Rev 1 strain was obtained from the *B. melitensis* culture collection (Razi Institute, Mashhad, Iran) and cultured, as described in the literature (Delpino et al., 2007). DNA was extracted, using a DNA extraction kit (Bioneer, Korea). The quality and purity of the extracted DNA were analyzed by agarose gel electrophoresis and a NanoDrop spectrophotometer (Sigma, USA). *Escherichia coli* strain DH5 $\alpha$  was used as the host for cloning, sequencing, and maintaining different DNA fragments. T/A cloning vector pTZ57R/T (Thermo, USA) was used for cloning and sequencing the amplified gene.

**PCR amplification.** Genomic DNA of *B. melitensis* Rev 1 was used as the template for amplifying the full-length ORF of *Omp31* gene (723 bp), using *EX Taq* DNA polymerase (Takara, Japan). Specific primers with restriction sites at the 5' end (underlined) were designed, using Primer Premier 5 (Premier Biosoft International, USA), according to the available nucleotide sequences on NCBI GenBank database (Table 1). Polymerase chain reaction (PCR) was performed in a reaction mixture, containing 2.5  $\mu$ l of 10X PCR buffer, 2  $\mu$ l of MgCl $_2$ , 2  $\mu$ l of dNTPs, 0.5  $\mu$ l of DNA solution (50-100 ng/ $\mu$ l), 1.5  $\mu$ l of mix primer (5 pmol/ $\mu$ l), and 0.125 U/ $\mu$ l of *EX Taq* DNA polymerase; also, deionized water was added to reach a final volume of 25  $\mu$ l. The PCR program was performed with an initial denaturation at 94  $^{\circ}$ C for 6 min, followed by 30 cycles of denaturation at 94  $^{\circ}$ C for 30 sec, annealing at 58  $^{\circ}$ C for 30 sec, extension at 72  $^{\circ}$ C for 45 sec, and a final extension at 72 $^{\circ}$ C for 10 min.

**Table 1.** Specific primers with restriction sites

Gene	Primer sequences (5' 3')	Restriction enzyme	Length (bp)
<i>Omp31</i>	F: <u>GAATTC</u> ATGAAATCCGTAATTTTGGC	<i>EcoRI</i>	723
	R: <u>GGATCC</u> TTAGAACTTGTAGTTCAGACCG	<i>BamHI</i>	

**Table 2.** Validation of bioinformatic software programs used in the present study

Antigens	Predicted epitopes	Experimental epitopes	References
GroEL <sup>1</sup> for <i>Yersinia</i> species	28-42,78-92,178-185,275-290, <b>315-336</b> ,430-440,526-545	316-326	Yamaguchi et al.,1996
Dnak <sup>2</sup> for <i>Brucella</i> species	40-67,78-92,210-227,357-370, 523-537, <b>609-640</b>	617-637	Vizcaino et al.,1997
SOD <sup>3</sup> for <i>Brucella</i> species	44-50, <b>70-86,134-153,147-165</b>	75-86,136-150,149-62	Tabatabai et al.,1994

**Table 3.** Final B- and T-cell epitopes predicted in this study

Gene	No.	Final B-cell epitopes	Final T-cell epitopes
<i>Omp31</i>	1	<sup>23</sup> VVSEPSAPTAAPVDTF <sub>38</sub>	<sup>193</sup> YAINNNWTLKSEYLY <sub>207</sub>
	2	<sup>51</sup> YAGGKFKHPFSSFDKEDNEQVSG <sub>73</sub>	<sup>91</sup> NWQLDNGVVL <sub>100</sub>
	3	<sup>168</sup> GDDASALHTWSDKTKAGWTLS <sub>188</sub>	
	4	<sup>191</sup> AEYAINNNWTLKSE <sub>204</sub>	


**Table 4.** Protein digestion analysis of final B- and T-cell epitopes

Gene	No.	B-cell epitopes	Mass (Da)	pI	Undigested enzymes
<i>Omp31</i>	1	YAGGKFKHPFSSFDKEDNEQVSG	2574.75	5.5	Clostripain, cyanogen bromide, iodobenzoate, and trypsin R
	2	GDDASALHTWSDKTKAGWTLS	2247.78	5.3	Trypsin R, proline endopeptidase, cyanogen bromide, AspN, clostripain, and staphylococcal protease
	3	AEYAINNNWTLKSE	165.78	4.8	Trypsin R, proline endopeptidase, cyanogen bromide, AspN, and clostripain
		T-cell epitopes	Mass(Da)	pI	Undigested enzyme
<i>Omp31</i>	1	YAINNNWTLKSEYLY	1892.1	6	Trypsin R, proline endopeptidase, cyanogen bromide, AspN, and clostripain

**Table 5.** Antigenicity of the predicted epitopes

Gene	No.	Final B-cell epitopes	VaxiJen scores	Final T-cell epitopes	VaxiJen scores
<i>Omp31</i>	1	<sup>23</sup> VVSEPSAPTAAPVDTF <sub>38</sub>	0.2*	<sup>193</sup> YAINNNWTLKSEYLY <sub>207</sub>	1
	2	<sup>51</sup> YAGGKFKHPFSSFDKEDNEQVSG <sub>73</sub>	0.7	<sup>91</sup> NWQLDNGVVL <sub>100</sub>	0.08*
	3	<sup>168</sup> GDDASALHTWSDKTKAGWTLS <sub>188</sub>	0.7		
	4	<sup>191</sup> AEYAINNNWTLKSE <sub>204</sub>	1.2		

\*Probable Non-Antigen




**Figure 1.** PCR products of *OMP31* with the length of 723 bp

	1	2	3	4	5	6	7	8	9	10	11	12	13
omp31	1	100.00	100.00	100.00	100.00	100.00	100.00	99.86	99.86	99.86	99.86	99.45	98.62
<i>B. melitensis</i> NI.CP002932.1	2	0	100.00	100.00	100.00	100.00	100.00	99.86	99.86	99.86	99.86	99.45	98.62
<i>B. melitensis</i> M5-90.CP001852-1.1	3	0	0	100.00	100.00	100.00	100.00	99.86	99.86	99.86	99.86	99.45	98.62
<i>B. melitensis</i> M28.CP002460.1	4	0	0	0	100.00	100.00	100.00	99.86	99.86	99.86	99.86	99.45	98.62
<i>B. melitensis</i> strain 183.FJ654488.1	5	0	0	0	0	100.00	100.00	99.86	99.86	99.86	99.86	99.45	98.62
<i>B. melitensis</i> ATCC 23457.CP001489.1	6	0	0	0	0	0	100.00	99.86	99.86	99.86	99.86	99.45	98.62
<i>B. melitensis</i> 16M.AE008918.1	7	0	0	0	0	0	0	99.86	99.86	99.86	99.86	99.45	98.62
<i>B. suis</i> bv. 1 str. S2.CP006962.1	8	1	1	1	1	1	1	1	100.00	100.00	100.00	99.59	98.76
<i>B. suis</i> VBI22.CP003129.1	9	1	1	1	1	1	1	1	0	100.00	100.00	99.59	98.76
<i>B. pinnipedialis</i> B2/94.CP002079.1	10	1	1	1	1	1	1	0	0	100.00	100.00	99.59	98.76
<i>B. cetaceae</i> B14/94.AY484526.1	11	1	1	1	1	1	1	0	0	0	100.00	99.59	98.76
<i>B. melitensis</i> strain Rev1.GQ403950.1	12	4	4	4	4	4	4	3	3	3	3	3	88.34
<i>B. ovis</i> ATCC.CP000709.1	13	10	10	10	10	10	10	9	9	9	9	9	12

**Figure 2.** Pairwise comparison between the candidate gene and other species. The upper triangle shows the percentage of sequence identity and the lower triangle presents differences in each matrix. *Omp31* refers to *Omp31* gene of *B. melitensis* Rev 1 strain.



**Figure 3.** Phylogenetic tree of *B. melitensis* Rev 1 strain and other *Brucella* species. *Omp31* signifies *Omp31* gene of *B. melitensis* Rev 1 strain.



**Figure 4.** A) B-cell, T-cell, and common predicted epitopes for *Omp31*; A<sub>1</sub>) B-cell epitopes: amino acids 51-73, 168-188, and 191-204 presented by red, green, and blue colors, respectively, A<sub>2</sub>) T-cell epitopes: 193-207 (yellow), A<sub>3</sub>) similar epitopes between B- and T-cell epitopes: 191-204 (green).

**Cloning.** The PCR product was purified from the agarose gel by Ron's Agarose Gel Miniprep Kit (BioRon, Germany), according to the manufacturer's instructions. Based on the manufacturer's instructions, the purified PCR product was ligated into pTZ57R/T

cloning vector by T/A cloning strategy. Preparation of competent cells and transformation were performed as described in the literature (Sambrook and Russell, 2001). The recombinant vectors were transformed into competent *E. coli* DH5 $\alpha$ . The recombinant clone(s),

harboring plasmid DNA with inserts, were screened, based on their ampicillin resistance. The fidelity of *E. coli* DH5 $\alpha$  transformants was verified by PCR reaction, using M13 universal primers. The recombinant plasmids were purified, using Ron's Plasmid Mini Kit and confirmed by restriction enzyme digestion. Also, purified plasmids were subjected to sequencing at Bioneer Corporation (South Korea). The obtained sequences were studied through homology analysis and were aligned with other reported *Omp31* gene, using BLAST and CLC Main Workbench 5.5 (CLC Bio, USA), respectively.

#### **Prediction of secondary and tertiary structures.**

The secondary structure was predicted, using the improved self-optimized prediction method with alignment (SOPMA) software (available on [https://npsa-prabi.ibcp.fr/cgi-bin/npsa\\_automat.pl?page=/NPSA/npsa\\_sopma.html](https://npsa-prabi.ibcp.fr/cgi-bin/npsa_automat.pl?page=/NPSA/npsa_sopma.html)) (Geourjon and Deleage, 1995) with four conformational states (i.e., helix, sheet, turn, and coil) of candidate genes. In addition, the tertiary structure was analyzed by 3D Ligand Site, which is an online ligand-binding site prediction server (available on <http://www.sbg.bio.ic.ac.uk>) (Wass and Sternberg, 2009).

**Servers and software programs for B- and T-cell epitope prediction.** B- and T-cell epitopes of candidate genes were predicted, using different servers and software programs. ABCPred, BepiPred, BCPred, SVMTrip, and LEPS were used for B-cell prediction, while IEDB, SYFPEITHI, ProPred I, and ProPred were employed for T-cell prediction.

**Verification of the bioinformatic analysis approach.** In order to validate the predicted outputs, the results of three experimental epitope prediction studies were evaluated by bioinformatic tools, applied in the present study.

**Characterization of epitopes.** Final B- and T-cell epitope predictions were evaluated, using VaxiJen 2.0 server (available on <http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html>) for the prediction of protective antigens. In addition, enzymatic degradation

sites, mass (Da), and Isoelectric point (pI) were determined, using the protein digest server (available on <http://db.Systemsbio.net:8080/proteomicsToolkit/proteinDigest.html>).

## **RESULTS AND DISCUSSION**

**PCR amplification, cloning, and nucleotide sequencing analysis.** In this study, *OMP31* gene from *B. melitensis* Rev 1 strain was amplified. The accuracy of the fragment was visualized on 0.8% agarose gel electrophoresis (Figure 1). The PCR products were successfully ligated into pTZ57R/T cloning vector and transformed into competent *E. coli* DH5 $\alpha$  cells. After the selection of positive screen colonies by colony PCR, the integrity of recombinant plasmids was confirmed through restriction digestion. The sequencing of recombinant plasmids was performed with specific primers and universal M13 primer. The sequence was submitted to NCBI database under the accession number, KJ193851. The obtained sequence was analyzed, using BLAST and CLC Main Workbench 5.5. Based on the findings, *Omp31* gene sequence had 100% homology to *B. melitensis* species (*B. melitensis* NI, *B. melitensis* M28, *B. melitensis* 183, *B. melitensis* 16M, and *B. melitensis* ATCC), while exhibiting less similarity to *B. ovis* (Figure 2). In addition, the phylogenetic tree was drawn for confirming the results of genetic distance matrix. It was revealed that *B. melitensis* Rev 1 strain had a close homology to *B. melitensis* NI, *B. melitensis* M28, *B. melitensis* 183, *B. melitensis* 16M, and *B. melitensis* ATCC, as similarly observed in the pairwise comparison matrix (Figure 3).

**Prediction of the secondary structure.** We predicted the secondary structure of *Omp31*, using SOPMA server software. The results revealed that random coils,  $\beta$  turns,  $\alpha$  helices, and extended strands ( $\beta$  folds) accounted for 59.17%, 2.5%, 15.42%, and 22.92% of the structure, respectively. The greater proportion of the extended strands and random coils in the secondary structure of the protein was associated

with the increased likelihood of antigenic epitope formation.

**Verification of the bioinformatic analysis approach.** In order to validate all software programs used in the present study, three antigens, whose epitopes were experimentally determined (available on <http://www.iedb.org>), were selected and their epitopes were predicted, using bioinformatic tools. The predicted epitopes were compared with the results of experimental studies. The findings revealed that our *in silico* predicted epitopes were similar to the findings of experimental studies for all the selected antigens (Table 2).

**Prediction of B- and T-cell epitopes.** B-cell epitopes, as well as MHC-I (A-0101, A0201, and B-2705) and MHC-II (DRB1-0101 and DRB1-0401) classes of T-cell epitopes, were predicted, using different online software programs. For each program, epitopes with the highest score were selected as proper epitopes. Finally, four B-cell and two T-cell epitopes were selected with respect to the most conserved sequences in all the proposed epitopes (Table 3).

**Characterization of epitopes.** The results of analysis by the protein digest server for mass (Da), pI, and enzymatic degradation sites are presented in Table 4. The findings indicated that the majority of predicted epitopes lacked proteasome recognition sites. The candidate proteins with a score of 0.64 were identified as antigens by VaxiJen 2.0 server (threshold: 0.5). The antigenicity of the final predicted B- and T-cell epitopes is shown in Table 5. Furthermore, the results of VaxiJen 2.0 analysis indicated that five predicted epitopes showed antigenicity. Finally, the 3D structure of candidate epitopes was illustrated, using 3D Ligand Site server (Figure 4). The 3D structure analysis showed that all the predicted B- and T-cell epitopes were located outside the candidate antigen.

Several studies have predicted epitopes of desired antigens via computational approaches and have applied the findings in experimental studies in order to design epitope-based vaccines (Simon et al., 2010). In the present study, the dominant *B. melitensis* Rev 1

antigen was a candidate for cloning, molecular analysis, and epitope prediction. The results showed that the candidate gene could be successfully cloned. Moreover, molecular analysis revealed that *Omp31* sequence of *B. melitensis* Rev 1 is nearly similar to other *Brucella* species. The strong nucleotide identity of *Omp31* might be attributed to the high degree of genetic relatedness among *Brucella* species (Rajagunalan et al., 2013). Comprehensive bioinformatic analyses were performed on the candidate antigen by online B- and T-cell epitopic prediction servers. To confirm the results of our bioinformatic approaches, we analyzed three different antigens and compared the obtained computational outputs with the experimental results. The bioinformatic analysis for GroEL, Dnak, and SOD antigens was successfully confirmed, using experimentally achieved epitopes. In the present study, the final epitopic prediction results proposed five *Omp31* epitopes, which could be used as immune-dominant epitopes for the development of recombinant subunit vaccine against brucellosis. In this regard, Wang et al. (2014) in a recent epitope mapping experiment on *Omp31* antigen (as a *B. melitensis* OMP) found that amino acid residue 48-74 was the dominant epitope; this region was also predicted in the present study via bioinformatic analysis. Moreover, similar results have been reported for *Omp31* epitopes by Vizcaino et al. (1997) and Cassataro et al. (2005). Several studies have attempted to predict epitopes of the desired antigen by computational approaches and have used these findings to design epitopic-based vaccines (Li et al., 2013; Sekhavati et al., 2015; Yousefi et al., 2015). The results of secondary and tertiary structure analyses showed that the common predicted B- and T-cell epitopes were located in the random coil regions on the surface structure of candidate antigens. Random coil regions are located on the surface of the protein, where it is necessary for the surface structure to properly bind to ligands, with a high possibility of epitope formation (Li et al., 2013). To prevent degradation of peptides during antigen processing, epitopes should lack proteasome

recognition sites (Toes et al., 2001). In the present study, the predicted B- and T-cell epitopes were analyzed in terms of enzymatic degradation. The proposed epitopes lacked proteasome digestion sites for several dominant enzymes.

Although brucellosis is a common zoonotic disease among domestic animals, but up to now no recombinant vaccine has been developed. Therefore, the aim of the present study was to clone, analyze the sequence, and predict the epitopes of two candidate *B. melitensis* Omp31 antigens. Additionally, we aimed to confirm the predicted epitopes, using the results of experimental epitope prediction studies in order to design a suitable recombinant vaccine. Phylogenetic analysis showed that this gene was nearly similar in different *Brucella* species, and common B- and T-cell epitopes were predicted for Omp31 (amino acids 191-204). *In vitro* synthesis of the determined peptides and experimental validation are required for using the predicted epitopes as effective vaccines against *Brucella melitensis* pathogen. It is worth mentioning that our laboratory (Animal biotechnology lab of Animal science group of Ferdowsi university of Mashhad) has initiated research on this subject.

### Ethics

I hereby declare all ethical standards have been respected in preparation of the submitted article.

### Conflict of Interest

The authors declare that they have no conflict of interest.

### Grant Support

The present study was funded by INFS (infs.gov.ir) of I.R.I with grant No. 92041813.

### Acknowledgments

The authors would like to express their gratitude to INFS for their full support.

### References

Azimi, L., Khoramabadi, N., Mohabati Mobarez, A., Aslz, E., Harzandi, N., R., M., 2012. Survey of Protection of

- Recombinant Cell Surface Protein 31kDa from *Brucella melitensis* in BALB/c Mice. *Journal of Pure and Applied Microbiology* 6, 69-73.
- Berzofsky, J.A., 1985. Intrinsic and extrinsic factors in protein antigenic structure. *Science* 229 932-940.
- Buus, S., Lauemøller, S.L., P., W., 2003. Sensitive quantitative predictions of peptide-MHC binding by a 'Query by Committee' artificial neural network approach. *Tissue Antigens* 62 378-384.
- Cassataro, J., Estein, S.M., Pasquevich, K.A., Velikovskiy, C.A., de la Barrera, S., Bowden, R., Fossati, C.A., Giambartolomei, G.H., 2005. Vaccination with the recombinant *Brucella* outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against *Brucella melitensis* infection. *Infection and immunity* 73, 8079-8088.
- Chen, P., Rayner, S., Hu, K.H., 2011. Advances of bioinformatics tools applied in virus epitopes prediction. *Virologica Sinica* 26, 1-7.
- Cutler, S.J., Whatmore, A.M., Commander, N.J., 2005. Brucellosis--new aspects of an old disease. *Journal of applied microbiology* 98, 1270-1281.
- Delpino, M.V., Estein, S.M., Fossati, C.A., Baldi, P.C., Cassataro, J., 2007. Vaccination with *Brucella* recombinant DnaK and SurA proteins induces protection against *Brucella abortus* infection in BALB/c mice. *Vaccine* 25, 6721-6729.
- Donnes, P., Elofsson, A., 2002. Prediction of MHC class I binding peptides, using SVMHC. *BMC bioinformatics* 3, 25.
- Geourjon, C., Deleage, G., 1995. SOPMA: significant improvements in protein secondary structure prediction by consensus prediction from multiple alignments. *Computer applications in the biosciences : CABIOS* 11, 681-684.
- Ghasemi, A., Salari, M.H., Zarnani, A.H., Pourmand, M.R., Ahmadi, H., Mirshafiey, A., Jeddi-Tehrani, M., 2013. Immune reactivity of *Brucella melitensis*-vaccinated rabbit serum with recombinant Omp31 and DnaK proteins. *Iranian journal of microbiology* 5, 19-23.
- Gupta, V.K., Vohra, J., Kumari, R., Gururaj, K., Vihan, V.S., 2012. Identification of *Brucella* isolated from goats using Pst I site polymorphism at Omp2 gene loci. *Indian Journal of Animal Sciences* 82, 240-243.
- Hopp, T.P., Woods, K.R., 1981. Prediction of protein antigenic determinants from amino acid sequences. *Proceedings of the National Academy of Sciences of the United States of America* 78, 3824-3828.

- Karthik, K., Rathore, R., Verma, A.K., Tiwari, R., Dhama, K., 2013. Brucellosis – still it stings. *Livestock Technology* 2, 8-10.
- Li, Y., Liu, X., Zhu, Y., Zhou, X., Cao, C., Hu, X., Ma, H., Wen, H., Ma, X., Ding, J.B., 2013. Bioinformatic prediction of epitopes in the Emy162 antigen of. *Experimental and therapeutic medicine* 6, 335-340.
- Noguchi, H., Kato, R., Hanai, T., Matsubara, Y., Honda, H., Brusic, V., Kobayashi, T., 2002. Hidden Markov model-based prediction of antigenic peptides that interact with MHC class II molecules. *Journal of bioscience and bioengineering* 94, 264-270.
- Pappas, G., Papadimitriou, P., Christou, L., Akritidis, N., 2006. Future trends in human brucellosis treatment. *Expert opinion on investigational drugs* 15, 1141-1149.
- Ponomarenko, J.V., van Regenmortel, M.H.V., 2009. B-cell epitope prediction, John Wiley & Sons, Inc.
- Rajagunalan, S., Kumari, G., Gupta, S.K., Kumar, A., Agarwal, R.K., Rawool, D.B., Singh, D.K., 2013. Molecular characterization of Omp31 gene of Indian field Isolates of *Brucella melitensis*. *Indian Journal of Animal Sciences* 83 673–677.
- Sambrook, J., Russell, D.W., 2001. *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press.
- Sekhavati, M.H., Majidzadeh Heravi, R., Tahmoorespur, M., Yousefi, S., Abbassi-Dalooi, T., Akbari, R., 2015. Cloning, molecular analysis and epitopes prediction of a new chaperone GroEL *Brucella melitensis* antigen. *Iranian Journal of Basic Medical Sciences* 18, 499-505.
- Simon, G.G., Hu, Y., Khan, A.M., Zhou, J., Salmon, J., Chikhlikar, P.R., Jung, K.O., Marques, E.T., August, J.T., 2010. Dendritic cell mediated delivery of plasmid DNA encoding LAMP/HIV-1 Gag fusion immunogen enhances T cell epitope responses in HLA DR4 transgenic mice. *PloS one* 5, e8574.
- Steere, A.C., Drouin, E.E., Glickstein, L.J., 2011. Relationship between immunity to *Borrelia burgdorferi* outer-surface protein A (OspA) and Lyme arthritis. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 52 Suppl 3, s259-265.
- Toes, R.E., Nussbaum, A.K., Degermann, S., Schirle, M., Emmerich, N.P., Kraft, M., Laplace, C., Zwinderman, A., Dick, T.P., Muller, J., Schonfisch, B., Schmid, C., Fehling, H.J., Stevanovic, S., Rammensee, H.G., Schild, H., 2001. Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. *The Journal of experimental medicine* 194, 1-12.
- Vahedi, F., Talebi, A.F., Ghorbani, E., Behroozikhah, A.M., Shahriari Ahmadi, F., Mahmoudi, M., 2011. Isolation, cloning and expression of the *Brucella melitensis* Omp31 gene. *Iranian Journal of Veterinary Research* 12, 156-162.
- Vizcaino, N., Cloeckaert, A., Zygmunt, M.S., Dubray, G., 1996. Cloning, nucleotide sequence, and expression of the *Brucella melitensis* omp31 gene coding for an immunogenic major outer membrane protein. *Infection and immunity* 64, 3744-3751.
- Vizcaino, N., Zygmunt, M.S., Verger, J.M., Grayon, M., Cloeckaert, A., 1997. Localization and characterization of a specific linear epitope of the *Brucella* DnaK protein. *FEMS microbiology letters* 154, 117-122.
- Wang, W., Wu, J., Qiao, J., Weng, Y., Zhang, H., Liao, Q., Qiu, J., Chen, C., Allain, J.P., Li, C., 2014. Evaluation of humoral and cellular immune responses to BP26 and OMP31 epitopes in the attenuated *Brucella melitensis* vaccinated sheep. *Vaccine* 32, 825-833.
- Wass, M.N., Sternberg, M.J., 2009. Prediction of ligand binding sites using homologous structures and conservation at CASP8. *Proteins* 77 Suppl 9, 147-151.
- Yousefi, S., Tahmoorespur, M., Sekhavati, M.H., 2015. B and T-cell epitope prediction of the OMP25 antigen for developing *Brucella melitensis* vaccines for sheep. *Iranian Journal of Applied Animal Science* 5, 629-638.
- Zhang, W., Liu, J., Zhao, M., Li, Q., 2012. Predicting linear B-cell epitopes by using sequence-derived structural and physicochemical features. *International journal of data mining and bioinformatics* 6, 557-569.